Altay Biopharma

Altay Biopharma, also known as Altay Therapeutics, is a company that is developing a novel small molecule inhibitor (ALT-CP4) for fibrosis, which targets a cellular protein that regulates matrix deposition and immune activation. The company has developed a novel platform that uses primary tissues which represents a more clinically relevant heterogeneous cell population. It is generating gene signatures from each active compound which will allows for assaying for broad changes in gene activation in choosing which small molecule to proceed. Its first clinical lead is idiopathic pulmonary fibrosis (IPF).

Its small molecules have potent inhibitor activity against disease-causing transcription factors by disrupting their association with DNA.

Its novel approach enables the identification of new transcription factors as targets for a wide range of diseases. Using its know-how and robust drug screening approach, it is able to develop potent small molecule drugs targeting disease-causing transcription factors.

Its small molecules have shown exceptional results in several animal models for fibrotic diseases and several cancers.

Altay Biopharma is a biotechnology company developing therapies aimed at increasing the lifespan of people living with fibrotic diseases that is headquartered in San Bruno, California and was founded in 2017.

Altay’s lead compound ALT-CP1 targets inflammation and has been demonstrated pre-clinical efficacy for treating lung and liver fibrosis in mouse models.